Equities

Egetis Therapeutics AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Egetis Therapeutics AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)4.70
  • Today's Change-0.10 / -2.09%
  • Shares traded266.06k
  • 1 Year change-14.79%
  • Beta0.9127
Data delayed at least 15 minutes, as of Feb 17 2026 11:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments351303128
Total Receivables, Net243610
Total Inventory1.000.700.60
Prepaid expenses4.505.508.90
Other current assets, total------
Total current assets380346147
Property, plant & equipment, net2.604.402.70
Goodwill, net------
Intangibles, net408409410
Long term investments0.800.800.80
Note receivable - long term------
Other long term assets0.20----
Total assets792760561
LIABILITIES
Accounts payable262920
Accrued expenses1376324
Notes payable/short-term debt000
Current portion long-term debt/capital leases337.401.60
Other current liabilities, total8.704.804.10
Total current liabilities20410449
Total long term debt851061.10
Total debt1171132.70
Deferred income tax0.50----
Minority interest------
Other liabilities, total105.104.40
Total liabilities29921555
SHAREHOLDERS EQUITY
Common stock201511
Additional paid-in capital2,0581,7801,428
Retained earnings (accumulated deficit)(1585)(1250)(934)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.10----
Total equity493546506
Total liabilities & shareholders' equity792760561
Total common shares outstanding359293215
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.